UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

The lancet oncology, 2022-08, Vol.23 (8), p.1055-1065

2022

Volltextzugriff (PDF)

Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling

CPT: pharmacometrics and systems pharmacology, 2024-02, Vol.13 (2), p.234-246

2024

Volltextzugriff (PDF)

The role of clinical pharmacology across novel treatment modalities

Clinical pharmacology and therapeutics, 2020-09, Vol.108 (3), p.413-415

2020

Volltextzugriff (PDF)

Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL

Clinical and translational science, 2023-07, Vol.16 (7), p.1134-1148

2023

Volltextzugriff (PDF)

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Journal of clinical pharmacology, 2018-03, Vol.58 (3), p.294-303

2018

Volltextzugriff (PDF)

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program

Clinical pharmacology and therapeutics, 2024-08, Vol.116 (2), p.282-288

2024

Volltextzugriff (PDF)

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients

Clinical pharmacology and therapeutics, 2019-02, Vol.105 (2), p.486-495

2019

Volltextzugriff (PDF)

Toll-like Receptor 2 Mediates VEGF Overexpression and Mesothelial Hyperpermeability in Tuberculous Pleural Effusion

International journal of molecular sciences, 2023-02, Vol.24 (3), p.2846

2023

Volltextzugriff (PDF)

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

NPJ systems biology and applications, 2020-08, Vol.6 (1), p.28-28, Article 28

2020

Volltextzugriff (PDF)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program

Clinical pharmacology and therapeutics, 2021-11, Vol.110 (5), p.1172-1175

2021

Volltextzugriff (PDF)

Glabridin, a Bioactive Flavonoid from Licorice, Effectively Inhibits Platelet Activation in Humans and Mice

International journal of molecular sciences, 2022-10, Vol.23 (19), p.11372

2022

Volltextzugriff (PDF)

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities

Clinical and translational science, 2021-01, Vol.14 (1), p.75-85

2021

Volltextzugriff (PDF)

A novel 2‐aminobenzimidazole‐based compound Jzu 17 exhibits anti‐angiogenesis effects by targeting VEGFR‐2 signalling

British journal of pharmacology, 2019-10, Vol.176 (20), p.4034-4049

2019

Volltextzugriff (PDF)

Decreased Human Platelet Activation and Mouse Pulmonary Thrombosis by Rutaecarpine and Comparison of the Relative Effectiveness with BAY11-7082: Crucial Signals of p38-NF-κB

Molecules (Basel, Switzerland), 2022-01, Vol.27 (2), p.476

2022

Volltextzugriff (PDF)

Artificial intelligence classification model for macular degeneration images: a robust optimization framework for residual neural networks

BMC bioinformatics, 2021-11, Vol.22 (Suppl 5), p.1-148, Article 148

2021

Volltextzugriff (PDF)

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

Clinical and translational science, 2024-06, Vol.17 (6), p.e13825-n/a

2024

Volltextzugriff (PDF)

Regulation of Human Platelet Activation and Prevention of Arterial Thrombosis in Mice by Auraptene through Inhibition of NF-κB Pathway

International journal of molecular sciences, 2020-07, Vol.21 (13), p.4810

2020

Volltextzugriff (PDF)

Suppression of reactive oxygen species‐mediated ERK and JNK activation sensitizes dihydromyricetin‐induced mitochondrial apoptosis in human non‐small cell lung cancer

Environmental toxicology, 2017-04, Vol.32 (4), p.1426-1438

2017

Volltextzugriff (PDF)

Hypersensitivity of Airway Reflexes Induced by Hydrogen Sulfide: Role of TRPA1 Receptors

International journal of molecular sciences, 2020-05, Vol.21 (11), p.3929

2020

Volltextzugriff (PDF)

Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies

PloS one, 2017-08, Vol.12 (8), p.e0181815-e0181815

2017

Volltextzugriff (PDF)

Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis

International journal of molecular sciences, 2019-10, Vol.20 (20), p.5076

2019

Volltextzugriff (PDF)

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

Cancer Chemotherapy and Pharmacology, 2016-03, Vol.77 (3), p.459-476

2016

Volltextzugriff (PDF)

Comparative survival analysis of platinum‐based adjuvant chemotherapy for early‐stage squamous cell carcinoma and adenocarcinoma of the lung

Cancer medicine (Malden, MA), 2022-05, Vol.11 (10), p.2067-2078

2022

Volltextzugriff (PDF)

Volumetric additive manufacturing of silica glass with microscale computed axial lithography

Science (American Association for the Advancement of Science), 2022-04, Vol.376 (6590), p.308-312

2022

Volltextzugriff (PDF)

Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

PloS one, 2017-01, Vol.12 (1), p.e0169429-e0169429

2017

Volltextzugriff (PDF)

1 – 25 von 941

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(843)
Mit Volltextzugriff
(861)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(676)
Life Sciences & Biomedicine
(471)
Humans
(309)
Male
(181)
Female
(174)
Technology
(143)
Physical Sciences
(141)
Middle Aged
(118)
Animals
(112)
Adult
(105)
Aged
(99)
Engineering
(88)
Chemistry
(83)
Biological And Medical Sciences
(78)
Patients
(70)
Science & Technology - Other Topics
(70)
General & Internal Medicine
(68)
Medical Sciences
(64)
Pharmacology & Pharmacy
(63)
Risk Factors
(63)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling

The role of clinical pharmacology across novel treatment modalities

Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients

Toll-like Receptor 2 Mediates VEGF Overexpression and Mesothelial Hyperpermeability in Tuberculous Pleural Effusion

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program

Glabridin, a Bioactive Flavonoid from Licorice, Effectively Inhibits Platelet Activation in Humans and Mice

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities

A novel 2‐aminobenzimidazole‐based compound Jzu 17 exhibits anti‐angiogenesis effects by targeting VEGFR‐2 signalling

Decreased Human Platelet Activation and Mouse Pulmonary Thrombosis by Rutaecarpine and Comparison of the Relative Effectiveness with BAY11-7082: Crucial Signals of p38-NF-κB

Artificial intelligence classification model for macular degeneration images: a robust optimization framework for residual neural networks

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

Regulation of Human Platelet Activation and Prevention of Arterial Thrombosis in Mice by Auraptene through Inhibition of NF-κB Pathway

Suppression of reactive oxygen species‐mediated ERK and JNK activation sensitizes dihydromyricetin‐induced mitochondrial apoptosis in human non‐small cell lung cancer

Hypersensitivity of Airway Reflexes Induced by Hydrogen Sulfide: Role of TRPA1 Receptors

Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies

Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

Comparative survival analysis of platinum‐based adjuvant chemotherapy for early‐stage squamous cell carcinoma and adenocarcinoma of the lung

Volumetric additive manufacturing of silica glass with microscale computed axial lithography

Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

Suchergebnisse filtern